For type 2 diabetes mellitus. ANDA 75965, held by Epic Pharma LLC. Metformin Hydrochloride.
As of Nov 16, 2026, ANDA 75965 (Metformin Hydrochloride), held by Epic Pharma LLC, was first approved by FDA on Jan 25, 2002, with 7 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Metformin hydrochloride tablets USP are indicated as an adjunct to diet and exercise to improve glycemic control in adults and children with type 2 diabetes mellitus. Metformin hydrochloride tablets USP are
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 25, 2002 | Original application | Approved | None posted |
| Metformin Hydrochloride500MG · tablet;oral | Metformin Hydrochloride | Rx |
| Metformin Hydrochloride850MG · tablet;oral | Metformin Hydrochloride | Rx |
| Metformin Hydrochloride1GM · tablet;oral | Metformin Hydrochloride | Rx |
| Aug 11, 2026 | Supplement 21Labeling · Standard review | Approved | None posted |
| Aug 28, 2019 | Supplement 18Labeling · Standard review | Approved | None posted |
| Aug 28, 2019 | Supplement 17Labeling · Standard review | Approved | None posted |
| May 20, 2010 | Supplement 12Labeling | Approved | None posted |
| Oct 2, 2002 | Supplement 3Manufacturing | Approved | None posted |
| Aug 22, 2002 | Supplement 2Labeling | Approved | None posted |
| Jul 1, 2002 | Supplement 1Manufacturing | Approved | None posted |
| Jan 25, 2002 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters